Clinical Determinants of the Six-Minute Walk Test (6MWT) in Stable Non-Cystic Fibrosis Bronchiectasis Patients

Ramin Sami 1, Mohammadali Zohal 2, Navid Mohammadi 3, 4

1 Department of Internal Medicine, Isfahan University of Medical Sciences, Isfahan, Iran, 2 Metabolic Disease Research Center, Qazvin University of Medical Sciences, Qazvin, Iran, 3 Department of Community Medicine, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran, 4 Preventive Medicine and Public Health Research Center (PMPHRC), Iran University of Medical Sciences, Tehran, Iran.

Received: 14 August 2019
Accepted: 8 January 2020

Correspondence to: Zohal MA
Address: Metabolic Disease Research Center, Qazvin University of Medical Sciences, Qazvin, Iran
Email address: zohal11@yahoo.com

INTRODUCTION

Bronchiectasis is recognized as a chronic pulmonary disease. The occurrence of this disease in one lobe is usually due to bronchial obstruction, while involvement of two or more lobes is attributed to either cystic fibrosis (CF) or non-CF causes. Generally, the CT scan findings of patients with bronchiectasis are diverse (1). The clinical course and treatment of CF bronchiectasis differ from non-CF bronchiectasis, because organs and systems other than the respiratory tract are involved. According to statistics, the frequency of bronchiectasis is increasing worldwide. A study from the United States showed that bronchiectasis has become more common in the general population (2); therefore, it can be considered as a public health concern. Also, the health consequences of this disease are important for the patients because of both pulmonary and systemic effects. Involvement of the airways, muscular weakness,
continuous inflammation, and cardiac complications can result in the decreased function of these patients (3).

Recent studies have reported a lower level of activity in bronchiectasis patients (4, 5). Different tests are used for the assessment of exercise capacity in patients (6). Although cardipulmonary exercise testing is the gold standard, it is not available in all settings as it requires advanced equipment; therefore, other tests are used as alternatives. The six-minute walk test (6MWT) is recognized as the most important alternative test. It is a relatively simple and precise tool for the assessment of exercise capacity (7) and widely used in daily practice (8). This test indicates the exercise capacity and prognosis of patients with pulmonary diseases, including bronchiectasis (9), and is used for the follow-up and assessment of treatment response (7).

The initial and most important endpoint in the 6MWT is the walked distance (6MWD) (7). A shorter 6MWD during the test is correlated with higher rates of mortality and hospital admission in bronchiectasis patients (7). Other than distance, an important parameter of this test is decreased arterial oxygen saturation (Sat₂O₂) during activity or exercise-induced desaturation (EID) (7). The Sat₂O₂ slightly increases during activity in healthy individuals, while it reduces in patients with pulmonary diseases. A more advanced stage of the disease is correlated with a lower Sat₂O₂. Continuous measurement of saturation during the test is important, because the lowest amount of oxygen saturation is not necessarily the final recorded value (10, 11).

The EID represents a reduction in blood oxygen during daily activities. It has been recently shown that EID in patients with pulmonary diseases is correlated not only with daily activity impairments, but also with a poor prognosis (9, 12, 13). Therefore, finding the predictors of EID may help us identify patients who require O₂ therapy during activity. Despite the importance of finding the determinants of 6MWT in bronchiectasis patients, there are limited studies in this area. All previous studies have focused on the determinants of 6MWD and reported inconsistent results (14-16). Age, sex, spirometry, and CT scan findings seem to have different effects on 6MWD, while their effects on EID have not been investigated. Therefore, this study aimed to assess the determinants of 6MWD, EID, and pretest Sat₂O₂ in patients with diffuse non-CF bronchiectasis.

**MATERIALS AND METHODS**

**Setting and patients**

In this cross-sectional study, which was conducted in Qazvin, Iran, a total of 57 patients (≥18 years) with diffuse non-CF bronchiectasis (involvement of two or more lobes of the lungs), were enrolled from October 2015 to October 2017. Patients were excluded from the study if they had a history of tuberculosis or any comorbidities. Patients were invited to participate in the study, and written consent forms were collected after the researcher explained the study objectives and methods.

**Data collection**

On the day of admission, a physician assessed the participants to collect the demographic data.

**Anthropometric measurements:** The patients’ weight and height were measured with precision of 500 g and 1 cm, respectively. The body mass index (BMI) was also calculated based on weight (kg) and height (m²). A BMI <18.5 kg/m² was considered as underweight, while BMI >25 kg/m² and BMI >30 kg/m² were considered as overweight and obese, respectively (17). The mid-arm muscle circumference (MAMC) was measured at the middle of the arm. Also, the triceps skinfold thickness (TSF) was assessed in the same area by using a standard caliper (Vogel, Germany). The percentiles of MAMC and TSF were calculated for each patient by using standard curves, and all values less than 25% were regarded as malnutrition.

**Spirometry:** Spirometry was carried out, according to the American Thoracic Society (ATS) guidelines (Jaeger Ltd., Hochberg, Germany) (18). Values and percentages of forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and FEV1/FVC ratio were
The severity of disease was defined based on FEV1 (severe: FEV1<50% predicted; moderate: 50%≤FEV1<80% predicted; and mild: FEV1≥80% predicted).

**Imaging assessment:** High-resolution computed tomography (HRCT) was performed according to the criteria proposed by Naidich et al. (19). The extent of disease was evaluated using a modified scoring system developed by Bhalla et al. (20). All CT scans were acquired and scored by a skilled radiologist.

**Bacteriological studies:** Morning sputum samples were collected after mouth washing and sent to the laboratory. Smears were studied, as well as cultures in a normal medium. The patients were categorized into three groups, based on the isolated microorganisms from the smears and cultures: Pseudomonas aeruginosa infections, non-Pseudomonas infections, and no infection. All patients received a 50-mL scaled container and were asked to report the volume of sputum in 24 hours.

**6MWT:** This test was performed for all patients on the day of admission. It included walking for 30 meters at three-meter intervals, based on the ATS guideline (7). The researcher accompanied the patients during the test and documented the results of tests, including 6MWD, Sat\textsubscript{a}O\textsubscript{2} at rest, and changes in Sat\textsubscript{a}O\textsubscript{2} during the test.

**Statistical analysis**

All numerical data are summarized as mean, standard deviation (SD), median, minimum, and maximum. Categorical data are also expressed as ratio and percentage. For evaluating differences between patients with different severities of the disease, analysis of variance (ANOVA) was performed, along with post-hoc analysis (Tukey’s HSD), if applicable. Moreover, correlation and linear regression analyses with backward elimination were performed to determine the predictors of 6MWT results. All analyses were performed in SPSS version 22. P-value less than 0.05 was considered statistically significant in all analyses.

**RESULTS**

A total of 57 patients (22 males and 35 females) with a definite diagnosis of bronchiectasis were analyzed in this study. The mean age (±SD) of the patients was 44.14±15.8 years (range: 18-72 years). The descriptive data, anthropometric indices, spirometric findings, and 6MWT results are shown in Table 1. Based on the FEV1 values, bronchiectasis patients were categorized into three groups in terms of disease severity: severe (n=26), moderate (n=16), and mild (n=15). Evaluation of data according to this categorization is shown in Figure 1. The mean 6MWD was 427.73±92.07 m in severe bronchiectasis patients and 439.63±102.65 m and 485.87±80.47 m in the moderate and mild groups, respectively; however, the results of ANOVA test showed no significant difference between the groups (P=0.153).

**Table 1.** The anthropometric, spirometry and 6MWT characteristics of the patients

| Test / index | Mean (SD) | Median | Minimum | Maximum |
|--------------|-----------|--------|---------|---------|
| **Anthropometric indices** | | | | |
| BMI (kg/m\textsuperscript{2}) | 25.02 (6.48) | 25.08 | 13.49 | 40.37 |
| MAMC (cm) | 15.35 (8.47) | 15.23 | .40 | 34.00 |
| TSF (mm) | 5.29 (4.19) | 4.00 | 0.50 | 17.50 |
| FEV1 (%) | 57.49 (23.32) | 53.90 | 22.30 | 131.60 |
| FVC (%) | 69.73 (20.04) | 67.00 | 35.00 | 128.50 |
| FEV1/FVC | 66.77 (12.11) | 66.77 | 42.51 | 89.95 |
| **Spirometry** | | | | |
| 6MWD (m) | 447.11 (94.59) | 455.50 | 162.00 | 636.00 |
| 6MWD (%) | 73.46 (12.96) | 76.00 | 33.00 | 99.00 |
| **6MWT measures** | | | | |
| Sat\textsubscript{a}O\textsubscript{2} at rest (%) | 91.79 (5.17) | 93.00 | 74.00 | 99.00 |
| Sat\textsubscript{a}O\textsubscript{2} after 6MWT (%) | 88.41 (9.99) | 91.00 | 37.00 | 98.00 |
| EID (%) | 3.32 (7.65) | 2.00 | -3.00 | 13.00 |
The 6MWD percentile was 73.55±14.56%, 72.77±13.79%, and 75.73±10.98% in the severe, moderate, and mild bronchiectasis groups, respectively; the difference between the groups was not significant (P=0.817). The SatO2 at rest was also examined in the groups. The SatO2 was 88.92±5.59% in the severe bronchiectasis group and 93.75±3.36% and 94.87±2.88% in the moderate and mild groups, respectively; there was a significant difference between the groups (P<0.001). The results of post-hoc analysis (Tukey’s HSD test) showed a significant difference between the severe bronchiectasis group and both moderate and mild groups (P=0.003 and P<0.001, respectively); nevertheless, the moderate and mild groups were not significantly different (P=0.765).

Regarding the FEV1/FVC ratio, the patients were categorized into two groups of obstructive disease (<70%) and non-obstructive disease (≥70%). The 6MWD was significantly different between these two groups. The patients with an obstructive disease had an average 6MWD of 431.95±95.61 m, while the non-obstructive group had a mean 6MWD of 490.64±75.17 m (P=0.041). Also, the mean 6MWD percentile in the obstructive and non-obstructive groups was 73.34±14.11% and 75.64±10.70% m, respectively, without any significant difference (P=0.579). Moreover, analysis of SatO2 at rest did not indicate any significant differences between the groups (P=0.104).

The 6MWD showed a significant inverse correlation with BMI (r=-0.434, P=0.001) and sputum volume (r=-0.315, P=0.023). Conversely, the correlation between the 6MWD percentile (r=0.531, P=0.001) and SatO2 at rest was found to be positive (r=0.291, P=0.028). A linear regression analysis was performed to find significant factors in
6MWD. Using a backward elimination method, the remaining factors in the model were BMI, Sat\textsubscript{a}O\textsubscript{2} at rest, MAMC, and FVC (Table 2), which were considered for the accurate prediction of 6MWD.

Moreover, a linear regression analysis was performed to find possible significant predictors of Sat\textsubscript{a}O\textsubscript{2} at rest. Based on the backward method, the remaining predictors with significant effects on Sat\textsubscript{a}O\textsubscript{2} included BMI, FEV\textsubscript{1}, and FEV\textsubscript{1}/FVC ratio (Table 3). These factors were considered for an accurate prediction of Sat\textsubscript{a}O\textsubscript{2} at rest in patients. Finally, a logistic regression analysis was conducted to determine effective factors in EID. According to the backward Wald stepwise elimination, the extent of bronchiectasis in CT scan was the only effective factor in reducing Sat\textsubscript{a}O\textsubscript{2} (95% CI: 0.293-0.963, P=0.0371).

### Table 2. Factors remained in the model: predictors for the 6MWD

| Standardized Coefficients | p-value | 95% Confidence Interval for \( \beta \) |
|---------------------------|---------|--------------------------------------|
| Constant                  | \( \alpha = -161.132 \) | 0.497 | -638.731 | 316.467 |
| FVC                       | \( \beta = 0.253 \) | 0.073 | -0.174 | 3.716 |
| Sat\textsubscript{a}O\textsubscript{2} at rest | \( \beta = 0.337 \) | 0.018* | 1.147 | 11.529 |
| BMI                       | \( \beta = -0.414 \) | 0.009* | -10.346 | -2.199 |

*statistically significant

### Table 3. Factors remained in the model: predictors for the Sat\textsubscript{a}O\textsubscript{2} at rest

| Standardized Coefficients | p-value | 95% Confidence Interval for \( \beta \) |
|---------------------------|---------|--------------------------------------|
| (Constant)                | \( \alpha = 17.345 \) | 0.021* | 2.745 | 31.945 |
| FEV\textsubscript{1}      | \( \beta = 0.375 \) | 0.002* | 0.050 | 0.210 |
| FEV\textsubscript{1}/FVC  | \( \beta = -0.221 \) | 0.054 | -0.210 | 0.002 |
| BMI                       | \( \beta = 0.146 \) | 0.060 | -0.005 | 0.239 |

*: statistically significant.

### DISCUSSION

A total of 57 patients (22 males and 35 females) with a definite diagnosis of bronchiectasis were analyzed in this study. The mean age (±SD) of the patients was 44.14±15.8 years (range: 18-72 years). The descriptive data, anthropometric indices, spirometric findings, and 6MWT results are shown in Table 1. Based on the FEV\textsubscript{1} values, bronchiectasis patients were categorized into three groups in terms of disease severity: severe (n=26), moderate (n=16), and mild (n=15). Evaluation of data according to this categorization is shown in Figure 1. The mean 6MWD was 427.73±92.07 m in severe bronchiectasis patients and 439.63±102.65 m and 485.87±80.47 m in the moderate and mild groups, respectively; however, the results of ANOVA test showed no significant difference between the groups (P=0.153).

The 6MWD percentile was 73.55±14.56%, 72.77±13.79%, and 75.73±10.98% in the severe, moderate, and mild bronchiectasis groups, respectively; the difference between the groups was not significant (P=0.817). The Sat\textsubscript{a}O\textsubscript{2} at rest was also examined in the groups. The Sat\textsubscript{a}O\textsubscript{2} was 88.92±5.59% in the severe bronchiectasis group and 93.75±3.36% and 94.87±2.88% in the moderate and mild groups, respectively; there was a significant difference between the groups (P<0.001). The results of post-hoc analysis (Tukey’s HSD test) showed a significant difference between the severe bronchiectasis group and both moderate and mild groups (P=0.003 and P<0.001, respectively); nevertheless, the moderate and mild groups were not significantly different (P=0.765).

Regarding the FEV\textsubscript{1}/FVC ratio, the patients were categorized into two groups of obstructive disease (<70%) and non-obstructive disease (≥70%). The 6MWD was significantly different between these two groups. The patients with an obstructive disease had an average 6MWD of 431.95±95.61 m, while the non-obstructive group had a mean 6MWD of 490.64±75.17 m (P=0.041). Also, the mean 6MWD percentile in the obstructive and non-obstructive groups was 73.34±14.11% and 75.64±10.70% m, respectively, without any significant difference (P=0.579). Moreover, analysis of Sat\textsubscript{a}O\textsubscript{2} at rest did not indicate any significant differences between the groups (P=0.104).

The 6MWD showed a significant inverse correlation with BMI (r=-0.434, P=0.001) and sputum volume (r=-0.315, P=0.023). Conversely, the correlation between the
6MWD percentile (r=0.531, P<0.001) and S\textsubscript{a}O\textsubscript{2} at rest was found to be positive (r=0.291, P=0.028). A linear regression analysis was performed to find significant factors in 6MWD. Using a backward elimination method, the remaining factors in the model were BMI, S\textsubscript{a}O\textsubscript{2} at rest, MAMC, and FVC (Table 2), which were considered for the accurate prediction of 6MWD.

Moreover, a linear regression analysis was performed to find possible significant predictors of S\textsubscript{a}O\textsubscript{2} at rest. Based on the backward method, the remaining predictors with significant effects on S\textsubscript{a}O\textsubscript{2} included BMI, FEV\textsubscript{1}, and FEV\textsubscript{1}/FVC ratio (Table 3). These factors were considered for an accurate prediction of S\textsubscript{a}O\textsubscript{2} at rest in patients. Finally, a logistic regression analysis was conducted to determine effective factors in EID. According to the backward Wald stepwise elimination, the extent of bronchiectasis in CT scan was the only effective factor in reducing S\textsubscript{a}O\textsubscript{2} (95% CI: 0.293-0.963, P=0.0371).

**CONCLUSION**

Based on the present results, FEV\textsubscript{1}, FEV\textsubscript{1}/FVC, and BMI were independent predictors of S\textsubscript{a}O\textsubscript{2} at rest in bronchiectasis patients. Also, FVC, S\textsubscript{a}O\textsubscript{2} at rest, BMI, and MAMC were related to 6MWD. The extent of pulmonary involvement in CT scans was the only predictor of EID during the test. However, age and sex were not significantly associated with the 6MWT results.

**Acknowledgement**

This research was supported by Qazvin University of Medical Sciences

**Conflict of Interest:** None to declare

**REFERENCES**

1. Schäfer J, Griese M, Chandrasekaran R, Chotirmall SH, Hartl D. Pathogenesis, imaging and clinical characteristics of CF and non-CF bronchiectasis. *BMC Pulm Med* 2018;18(1):79.

2. Weycker D, Hansen GL, Seifer FD. Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013. *Chron Respir Dis* 2017;14(4):377-384.

3. Ozalp O, Inal-Ince D, Calik E, Vardar-Yaglı N, Saglam M, Savei S, et al. Extrapulmonary features of bronchiectasis: muscle function, exercise capacity, fatigue, and health status. *Multidiscip Respir Med* 2012;7(1):3.

4. Bradley JM, Wilson JJ, Hayes K, Kent L, McDonough S, Tully MA, et al. Sedentary behaviour and physical activity in bronchiectasis: a cross-sectional study. *BMC Pulm Med* 2015;15:61.

5. José A, Ramos TM, de Castro RAS, de Oliveira CS, de Camargo AA, Athanazio RA, et al. Reduced Physical Activity With Bronchiectasis. *Respir Care* 2018;63(12):1498-1505.

6. Adachi H. Cardiopulmonary Exercise Test. *Int Heart J* 2017;58(5):654-665.

7. Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. *Eur Respir J* 2014;44(6):1428-46.

8. Spruit MA, Watkins ML, Edwards LD, Vestbo J, Calverley PM, Pinto-Plata V, et al. Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. *Respir Med* 2010;104(6):849-57.

9. Hsieh MH, Fang YF, Chung FT, Lee CS, Chang YC, Liu YZ, et al. Distance-saturation product of the 6-minute walk test predicts mortality of patients with non-cystic fibrosis bronchiectasis. *J Thorac Dis* 2017;9(9):3168-3176.

10. Chuang ML, Lin IF, Chen SP. Kinetics of changes in oxyhemoglobin saturation during walking and cycling tests in COPD. *Respir Care* 2014;59(3):353-62.

11. Fiore C, Lee A, McDonald C, Hill C, Holland A. Should oxyhaemoglobin saturation be monitored continuously during the 6-minute walk test? *Chron Respir Dis* 2011;8(3):181-4.

12. van Gestel AJ, Clarenbach CF, Stöwhas AC, Teschler S, Russi EW, Teschler H, et al. Prevalence and prediction of exercise-induced oxygen desaturation in patients with chronic obstructive pulmonary disease. *Respiration* 2012;84(5):353-9.

13. Casanova C, Cote C, Marin JM, Pinto-Plata V, de Torres JP, Aguirre-Jaíme A, et al. Distance and oxygen desaturation during the 6-min walk test as predictors of long-term mortality in patients with COPD. *Chest* 2008;134(4):746-52.

14. Guan WJ, Gao YH, Xu X, Tang Y, Li HM, et al. Six-minute walk test in Chinese adults with clinically stable bronchiectasis: association with clinical indices and determinants. *Curr Med Res Opin* 2015;31(4):843-52.
15. Yildiz S, Inal-Ince D, Calik-Kutukeu E, Vardar-Yagli N, Saglam M, Arikan H, et al. Clinical Determinants of Incremental Shuttle Walk Test in Adults with Bronchiectasis. *Lung* 2018;196(3):343-349.

16. Lee AL, Button BM, Ellis S, Stirling R, Wilson JW, Holland AE, et al. Clinical determinants of the 6-Minute Walk Test in bronchiectasis. *Respir Med* 2009;103(5):780-5.

17. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *Lancet* 2004;363(9403):157-63.

18. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. *Eur Respir J* 2005;26(2):319-38.

19. Naidich DP, Marshall CH, Gribbin C, Arams RS, McCauley DI. Low-dose CT of the lungs: preliminary observations. *Radiology* 1990;175(3):729-31.

20. Bhatta M, Turcios N, Aponte V, Jenkins M, Leitman BS, McCauley DI, et al. Cystic fibrosis: scoring system with thin-section CT. *Radiology* 1991;179(3):783-8.

21. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. *Lancet* 2012;380(9842):660-7.

22. Hernandes NA, Wouters EF, Meijer K, Annegarn J, Pitta F, Spruit MA. Reproducibility of 6-minute walking test in patients with COPD. *Eur Respir J* 2011;38(2):261-7.

23. Spruit MA, Polkey MI, Celli B, Edwards LD, Watkins ML, Pinto-Plata V, et al. Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. *J Am Med Dir Assoc* 2012;13(3):291-7.

24. Koulouris NG, Retso S, Kosmas E, Dimakou K, Malagaris K, Mantzikopoulos G, et al. Tidal expiratory flow limitation, dyspnoea and exercise capacity in patients with bilateral bronchiectasis. *Eur Respir J* 2003;21(5):743-8.

25. Jacques PS, Gazzana MB, Palombini DV, Barreto SS, Dalcin Pde T. Six-minute walk distance is not related to quality of life in patients with non-cystic fibrosis bronchiectasis. *J Bras Pneumol* 2012;38(3):346-55.

26. Contarini M, Finch S, Chalmers JD. Bronchiectasis: a case-based approach to investigation and management. *Eur Respir Rev* 2018;27(149):180016.